Abstract: Compositions and associated methods of preparing placental tissue products/compositions are disclosed together with methods of utilizing the placental tissue composition for delivery of a therapeutic agent.

Abstract: Methods of preparing placental tissue products/compositions are disclosed together with methods of utilizing the placental tissue composition for delivery of a therapeutic agent.

Abstract: A liquid formulation comprising an acellular extract of placental tissue and a solvent that may prevent the onset or reduce the symptoms of an intestinal condition in a subject when a therapeutically effective amount of the liquid formulation is delivered to a gastric system of the subject.

Abstract: A bracket is provided for an adjustable bed base that distributes the load of an actuator across a moveable panel of the adjustable bed. The bracket is coupled to a moveable panel of the adjustable bed, and has a width that is greater than one-third the width of the moveable panel.

Abstract: Compositions and associated methods of preparing placental tissue products/compositions are disclosed together with methods of utilizing the placental tissue composition for delivery of a therapeutic agent.

Abstract: Compositions and associated methods of preparing placental tissue products/compositions are disclosed together with methods of utilizing the placental tissue composition for delivery of a therapeutic agent.

Abstract: A bracket is provided for an adjustable bed base that distributes the load of an actuator across a moveable panel of the adjustable bed. The bracket is coupled to a moveable panel of the adjustable bed, and has a width that is greater than one-third the width of the moveable panel.

Abstract: Various biopsy devices configured to biopsy tissue from a body cavity and methods of use are provided. In an exemplary embodiment, a biopsy sleeve is provided with an elongate shaft having distal and proximal ends. The elongate shaft is configured to receive at least a portion of an imaging device therein, and an engagement member is disposed on the proximal end and configured to engage with the imaging device. A biopsy collector is engageable with the elongate shaft and is configured to collect tissue for a biopsy sample. At least part of the distal end of the elongate shaft is configured to allow visualization therethrough using the imaging device such that a user can visualize the tissue being collected.

Abstract: Biological products are disclosed that have improved qualities relative to those that are currently available. Disclosed are compositions and methods for modulating cellular physiology and pathological processing using compositions that are derived from various placenta/villous chorion tissue.

Abstract: Compositions and associated methods of preparing placental tissue products/compositions are disclosed together with methods of utilizing the placental tissue composition for delivery of a therapeutic agent.

Abstract: Various biopsy devices configured to biopsy tissue from a body cavity and methods of use are provided. In an exemplary embodiment, a biopsy sleeve is provided with an elongate shaft having distal and proximal ends. The elongate shaft is configured to receive at least a portion of an imaging device therein, and an engagement member is disposed on the proximal end and configured to engage with the imaging device. A biopsy collector is engageable with the elongate shaft and is configured to collect tissue for a biopsy sample. At least part of the distal end of the elongate shaft is configured to allow visualization therethrough using the imaging device such that a user can visualize the tissue being collected.

Abstract: Described herein are compositions of keratin-based biomaterials together with halofuginone and methods of using thereof.

Abstract: Described herein are compositions of keratin-based biomaterials together with halofuginone and methods of using thereof

Abstract: Provided herein are multimodal barrier materials useful for preventing adhesions in a subject, which may include a collagen, a collagen deposition inhibitor and/or a chitosan.

Abstract: The present invention relates to a method of using 17&agr;-dihydroequilenin and metabolic conjugates thereof to prevent and reduce atherogenesis in males and females without causing endometrial proliferation in females and without producing feminizing changes in males. 17&agr;-dihydroequilenin was evaluated for its effects on plasma lipid and lipoprotein, glucose, insulin concentrations, coronary artery vasomotor function, and reproductive organ and mammary gland proliferation in atherosclerotic mammals. 17&agr;-dihydroequilenin was found to prevent endothelium-dependent vasoconstriction in males (p<0.05) and ovariectomized females (p<0.08). 17&agr;-dihydroequilenin treatment increased plasma apolipoprotein A-1 concentrations (p<0.05) and lowered fasting insulin concentrations (p<0.05) without changing fasting plasma glucose concentrations in males. 17&agr;-dihydroequilenin had no other effects on plasma lipid and lipoprotein concentrations in either males or females.

Abstract: The present invention relates to a method of using 17.alpha.-dihydroequilenin and metabolic conjugates thereof to prevent and reduce atherogenesis in males and females without causing endometrial proliferation in females and without producing feminizing changes in males. 17.alpha.-dihydroequilenin was evaluated for its effects on plasma lipid and lipoprotein, glucose, insulin concentrations, coronary artery vasomotor function, and reproductive organ and mammary gland proliferation in atherosclerotic mammals. 17.alpha.-dihydroequilenin was found to prevent endothelium-dependent vasoconstriction in males (p<0.05) and ovariectomized females (p<0.08). 17.alpha.-dihydroequilenin treatment increased plasma apolipoprotein A-1 concentrations (p<0.05) and lowered fasting insulin concentrations (p<0.05) without changing fasting plasma glucose concentrations in males. 17.alpha.-dihydroequilenin had no other effects on plasma lipid and lipoprotein concentrations in either males or females. Also, 17.alpha.

Abstract: The present invention relates to a method of using 17.alpha.-dihydroequilenin and metabolic conjugates thereof to prevent and reduce atherogenesis in males and females without causing endometrial proliferation in females and without producing feminizing changes in males. 17.alpha.-dihydroequilenin was evaluated for its effects on plasma lipid and lipoprotein, glucose, insulin concentrations, coronary artery vasomotor function, and reproductive organ and mammary gland proliferation in atherosclerotic mammals. 17.alpha.-dihydroequilenin was found to prevent endothelium-dependent vasoconstriction in males (p<0.05) and ovariectomized females (p<0.08). 17.alpha.-dihydroequilenin treatment increased plasma apolipoprotein A-l concentrations (p<0.05) and lowered fasting insulin concentrations (p<0.05) without changing fasting plasma glucose concentrations in males. 17.alpha.-dihydroequilenin had no other effects on plasma lipid and lipoprotein concentrations in either males or females. Also, 17.alpha.

Abstract: A method of using a steroidal compound, 17.alpha.-dihydroequilenin, to prevent and treat neurodegeneration and cognitive dysfunction in estrogen deficient females and to reduce the risk of Alzheimer's related dementia and other senile dementia related conditions in both males and females. The method comprises administering 17.alpha.-dihydroequilenin in a therapeutically effective amount to a mammal in need of increased cognitive function or to a mammal susceptible to estrogen deficiency-related neurodegeneration or to senile dementia of the Alzheimer's type.

Abstract: This invention provides a method of lowering cholesterol and blood lipid levels, preventing hypercholesterolemia, hyperlipidemia, cardiovascular disease, atherosclerosis, and peripheral vascular disease comprising administering an effective amount of 17.alpha.-dihydroequilenin or a mammalian metabolic conjugate thereof to a mammal in need thereof.